News

Medicamen Biotech announced that the Board of Directors of the Company at its meeting held on 27 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Net profit of Medicamen Biotech rose 59.50% to Rs 3.86 crore in the quarter ended March 2026 as against Rs 2.42 crore during the previous quarter ended March 2025. Sales rose 104.83% to Rs 60.65 crore in the quarter ended March 2026 as against Rs 29.61 crore during the previous quarter ended March 2025.For the full year,net profit rose 35.58% to Rs 9.64 crore in the year ended March 2026 as against Rs 7.11 crore during the previous year ended March 2025. Sales rose 21.67% to Rs 197.77 crore in the year ended March 2026 as against Rs 162.55 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales60.6529.61 105 197.77162.55 22 OPM %8.97-5.44 -9.918.53 - PBDT6.792.97 129 19.2016.95 13 PBT5.062.49 103 11.989.88 21 NP3.862.42 60 9.647.11 36 Powered by Capital Market - Live News

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 27 May 2026.

Net profit of Medicamen Biotech declined 36.89% to Rs 2.19 crore in the quarter ended December 2025 as against Rs 3.47 crore during the previous quarter ended December 2024. Sales rose 3.92% to Rs 46.91 crore in the quarter ended December 2025 as against Rs 45.14 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales46.9145.14 4 OPM %9.3414.86 - PBDT3.946.09 -35 PBT2.113.88 -46 NP2.193.47 -37 Powered by Capital Market - Live News

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live News